298 related articles for article (PubMed ID: 20844009)
1. Mice lacking bone sialoprotein (BSP) lose bone after ovariectomy and display skeletal site-specific response to intermittent PTH treatment.
Wade-Gueye NM; Boudiffa M; Laroche N; Vanden-Bossche A; Fournier C; Aubin JE; Vico L; Lafage-Proust MH; Malaval L
Endocrinology; 2010 Nov; 151(11):5103-13. PubMed ID: 20844009
[TBL] [Abstract][Full Text] [Related]
2. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
3. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
[TBL] [Abstract][Full Text] [Related]
4. Deletion of OPN in BSP knockout mice does not correct bone hypomineralization but results in high bone turnover.
Bouleftour W; Juignet L; Verdière L; Machuca-Gayet I; Thomas M; Laroche N; Vanden-Bossche A; Farlay D; Thomas C; Gineyts E; Concordet JP; Renaud JB; Aubert D; Teixeira M; Peyruchaud O; Vico L; Lafage-Proust MH; Follet H; Malaval L
Bone; 2019 Mar; 120():411-422. PubMed ID: 30529011
[TBL] [Abstract][Full Text] [Related]
5. Absence of bone sialoprotein (BSP) impairs primary bone formation and resorption: the marrow ablation model under PTH challenge.
Wade-Gueye NM; Boudiffa M; Vanden-Bossche A; Laroche N; Aubin JE; Vico L; Lafage-Proust MH; Malaval L
Bone; 2012 May; 50(5):1064-73. PubMed ID: 22586700
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
[TBL] [Abstract][Full Text] [Related]
7. Blocking the expression of both bone sialoprotein (BSP) and osteopontin (OPN) impairs the anabolic action of PTH in mouse calvaria bone.
Bouleftour W; Bouet G; Granito RN; Thomas M; Linossier MT; Vanden-Bossche A; Aubin JE; Lafage-Proust MH; Vico L; Malaval L
J Cell Physiol; 2015 Mar; 230(3):568-77. PubMed ID: 25160656
[TBL] [Abstract][Full Text] [Related]
8. Differential transcriptional effects of PTH and estrogen during anabolic bone formation.
von Stechow D; Zurakowski D; Pettit AR; Müller R; Gronowicz G; Chorev M; Otu H; Libermann T; Alexander JM
J Cell Biochem; 2004 Oct; 93(3):476-90. PubMed ID: 15372627
[TBL] [Abstract][Full Text] [Related]
9. Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat.
Zhou H; Shen V; Dempster DW; Lindsay R
J Bone Miner Res; 2001 Jul; 16(7):1300-7. PubMed ID: 11450706
[TBL] [Abstract][Full Text] [Related]
10. Biglycan deficiency interferes with ovariectomy-induced bone loss.
Nielsen KL; Allen MR; Bloomfield SA; Andersen TL; Chen XD; Poulsen HS; Young MF; Heegaard AM
J Bone Miner Res; 2003 Dec; 18(12):2152-8. PubMed ID: 14672350
[TBL] [Abstract][Full Text] [Related]
11. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.
Christiansen P
APMIS Suppl; 2001; (102):1-52. PubMed ID: 11419022
[TBL] [Abstract][Full Text] [Related]
12. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
13. Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength.
Fox J; Miller MA; Newman MK; Metcalfe AF; Turner CH; Recker RR; Smith SY
Calcif Tissue Int; 2006 Oct; 79(4):262-72. PubMed ID: 16969596
[TBL] [Abstract][Full Text] [Related]
14. Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2.
Ferrari SL; Pierroz DD; Glatt V; Goddard DS; Bianchi EN; Lin FT; Manen D; Bouxsein ML
Endocrinology; 2005 Apr; 146(4):1854-62. PubMed ID: 15705780
[TBL] [Abstract][Full Text] [Related]
15. Absence of bone sialoprotein (BSP) impairs cortical defect repair in mouse long bone.
Malaval L; Monfoulet L; Fabre T; Pothuaud L; Bareille R; Miraux S; Thiaudiere E; Raffard G; Franconi JM; Lafage-Proust MH; Aubin JE; Vico L; Amédée J
Bone; 2009 Nov; 45(5):853-61. PubMed ID: 19524706
[TBL] [Abstract][Full Text] [Related]
16. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine.
Fox J; Miller MA; Newman MK; Turner CH; Recker RR; Smith SY
J Bone Miner Res; 2007 Feb; 22(2):260-73. PubMed ID: 17087625
[TBL] [Abstract][Full Text] [Related]
17. Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice.
Machado do Reis L; Kessler CB; Adams DJ; Lorenzo J; Jorgetti V; Delany AM
Bone; 2008 Aug; 43(2):264-273. PubMed ID: 18499553
[TBL] [Abstract][Full Text] [Related]
18. Mice lacking AMP-activated protein kinase α1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment.
Jeyabalan J; Shah M; Viollet B; Roux JP; Chavassieux P; Korbonits M; Chenu C
J Endocrinol; 2012 Sep; 214(3):349-58. PubMed ID: 22700192
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of SIBLING proteins and correlation with cognate MMP expression in oral cancer.
Ogbureke KU; Nikitakis NG; Warburton G; Ord RA; Sauk JJ; Waller JL; Fisher LW
Oral Oncol; 2007 Oct; 43(9):920-32. PubMed ID: 17306612
[TBL] [Abstract][Full Text] [Related]
20. Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice.
Pierroz DD; Rufo A; Bianchi EN; Glatt V; Capulli M; Rucci N; Cavat F; Rizzoli R; Teti A; Bouxsein ML; Ferrari SL
J Bone Miner Res; 2009 May; 24(5):775-84. PubMed ID: 19113915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
